{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-040222","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2023-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.222289+00:00","generated_at":"2026-06-07T20:39:40.231654+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arrowhead Pharma reports FY2023 net loss of $205M, pipeline advances","bullets":["Revenue $240.7M vs $243.2M YoY; net loss $205.3M (EPS -$1.92) vs $176.1M (-$1.67).","Cash and investments $403.6M, down from $482.3M; R&D spend up 19% to $353M.","Plozasiran (APOC3) showed up to 90% APOC3 reduction in Phase 2 severe hypertriglyceridemia.","Completed GLP tox for pulmonary candidates ARO-RAGE and ARO-MMP7; planning Phase 2.","GSK acquired full rights to JNJ-3989 (ARO-HBV) from Janssen; Arrowhead retains no further obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-040222","json":"https://secwatch.observer/filing/0001628280-23-040222.json","markdown":"https://secwatch.observer/filing/0001628280-23-040222.md","text":"https://secwatch.observer/filing/0001628280-23-040222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828023040222/0001628280-23-040222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828023040222/arwr-20231129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T20:39:40.231654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"257052b0c89f54ad00bb290910776cd2a4191ba8","claim":"ARROWHEAD PHARMACEUTICALS, INC. reported fiscal year ended September 30, 2023 results: revenue $ 240,735, net income $ (205,275), EPS $ (1.92).","evidence_excerpt":"PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended September 30, OPERATING SUMMARY 2023 2022 Revenue $ 240,735 $ 243,231 Operating Expenses: Research and development 353,188 297,307 General and administrative expenses 92,549 124,431 Total Operating Expenses 445,737 421,738 Operating loss","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023040222/0001628280-23-040222-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended September 30, 2023"},{"label":"Revenue","value":"$ 240,735"},{"label":"Net income","value":"$ (205,275)"},{"label":"EPS","value":"$ (1.92)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}